| Sep 26 |
Biogen to end Sage deal for neuro candidate
|
| Sep 26 |
Roche, Biogen kidney disease drug hits main goal in late-stage study
|
| Sep 25 |
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
|
| Sep 24 |
Biogen stock opened higher on positive lupus readout
|
| Sep 24 |
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
|
| Sep 24 |
Biogen, UCB mark late-stage trial win for autoimmune disease therapy
|
| Sep 24 |
UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released
|
| Sep 24 |
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
|
| Sep 24 |
Biogen, UCB get the lupus data they’ve waited two decades for
|
| Sep 23 |
Update: Wedbush Cuts Biogen's Price Target to $205 From $210 Due to Lack of 'Clear-Cut Revenue Driver', Keeps Neutral Rating
|
